Development and evaluation of nebulised oligonucleotide formulations for the treatment of chronic obstructive pulmonary disease.

Written By PY

Click the image to read the article.

Our latest case study on the development of inhaled oligonucleotide formulations for the treatment of chronic obstructive pulmonary disease (COPD) is now available for download from our Knowledge Hub and the Drug Delivery to the Lungs (DDL) conference portal. This innovative work showcases our expertise in inhaled biologics, including the formulation and optimization of nebulized splice-switching oligonucleotides (SSOs) for efficient lung delivery.

PY
Previous

Enhancing the intranasal delivery of mRNA therapeutics using a novel thermosensitive polymer
Next

Read Ab Initio & Oz-UK’s recent article highlighting advanced tools that we can use to ease MDI product development